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Innate immune responses including TLR4 and complement activation are required for mesenteric 
ischemia/reperfusion (IR)-induced tissue damage.  We examined the regulation of TLR4 and 
complement activation in a mouse model of intestinal IR. Intestinal IR induced C3 deposition in 
a TLR4 dependent manner. In addition, in wild-type but not TLR4 deficient mice, IR 
significantly increased C3 and Factor B (FB) mRNA expression within the intestine.  To further 
examine the role of TLR4 and complement, we administered the complement inhibitor, CR2-
Crry, to target local complement activation in wild-type C57Bl/10, and TLR4 deficient B10/ScN 
mice.  TLR4 deficient mice sustained less damage and inflammation after IR than wild-type 
mice, but administration of CR2-Crry did not further reduce tissue damage. In contrast, CR2-
Crry treatment of wild-type mice was accompanied by a reduction in complement activation and 
in C3 and FB transcription in response to IR. CR2-Crry also significantly decreased intestinal IL-
6 and IL-12p40 production in both the wild-type and TLR4 deficient mice. These data indicate 
that TLR4 regulates extrahepatic complement production while complement regulates TLR4-
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INTRODUCTION 
Mesenteric thrombosis/embolism induces an ischemic event which may be followed by 
reperfusion of the blood flow (Collard et al., 1999; Eror et al., 1999; Kilgore et al., 1999).  
Although transient ischemia induces biological and chemical changes which leads to tissue 
damage (Zhang and Carroll, 2006), reperfusion magnifies intestinal damage (Austen et al., 
1999).  Reperfusion also generates numerous inflammatory mediators including complement 
activation products, cytokines and eicosanoids (reviewed in (Kilgore et al., 1999)).  These 
mediators frequently lead to the inappropriate expression of adhesion molecules and neutrophil 
infiltration of local and remote tissues. The intense inflammatory response during mesenteric IR 
may lead to multiple organ failure, resulting in a mortality rate ranging from 60 – 80% in humans 
(Clark and Coopersmith, 2007; Deitch, 2001; Leaphart and Tepas, 2007).      
 
Complement is a significant component of the innate immune response and can be activated by 
multiple pathways to generate C3 opsonins, chemotactic peptides and the cytolytic terminal 
membrane attack complex on surface membranes.  Natural inhibitors protect host cells and 
tissues from damage caused by excessive or inappropriate activation of the complement cascade.  
Natural human membrane-bound inhibitors include complement receptor 1 (CR1), decay 
accelerating factor (DAF; CD55) and membrane cofactor protein (Makrides, 1998; Makrides, 
2000).  These proteins differ somewhat in their mechanisms of action, but all three proteins 
inhibit all complement pathways at the C3 activation step (Makrides, 2000).  In the mouse, 
complement receptor-related gene y (Crry) expresses an activity profile similar to that of CR1 in 
humans (Quigg et al., 1998). Administration of the recombinant soluble fusion proteins Crry-Ig 
(Rehrig et al., 2001) or CR2-Crry (Atkinson et al., 2005) attenuates intestinal IR-induced tissue 
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damage in wild-type mice. Crry-Ig systemically inhibits complement activation, whereas CR2-
Crry inhibits complement activation locally with minimal systemic effect by targeting to C3 
breakdown products deposited at sites of complement activation (Atkinson et al., 2005) 
However, it is unknown if CR2-Crry inhibits other components of the inflammatory response.  
 
Reperfusion-induced tissue damage releases damage associated molecular patterns, which may 
be recognized by toll like receptors (TLR).  Several reports suggest that TLR play a role in IR-
induced organ damage and inflammation (reviewed in (Arumugam et al., 2009)).  In multiple 
models of tissue damage, cellular debris and extracellular matrix degradation products including 
hyaluronic acid, fibronectin, fibrinogen and heparin sulfate induce “sterile inflammation” 
through the pattern recognition receptor, TLR4 (reviewed in (Mollen et al., 2006; Tsan and Gao, 
2004)).  We recently demonstrated that TLR4 expression is critical for Cox-2 induced 
prostaglandin E2 (PGE2) production during intestinal IR (Moses et al., 2009). In addition, 
stimulation of TLR4 on macrophages induces secretion of multiple cytokines including TNF, IL-
1, IL-6 and IL-12 (Akira and Hemmi, 2003; Tsan and Gao, 2004).  Expressed by both leukocytes 
and intestinal epithelial cells, TLR4 is critical to maintaining the intestinal epithelium’s tolerance 
to commensal LPS (Fukata et al., 2006; Fukata et al., 2007; Fukata et al., 2005).  Thus, multiple 
IR-induced inflammatory processes may be mediated by TLR4. 
 
As two components of the innate immune response, TLR4 and the complement cascade have 
recently been shown to interact.  The complement inhibitor DAF appears to bind LPS, and in 
conjunction with TLR4 and other proteins, make up the LPS receptor complex (El-Samalouti et 
al., 1999; Heine et al., 2001; Triantafilou et al., 2002).  In the absence of DAF, C3aR and C5aR 
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activation up-regulates TLR4 mediated IL-1, IL-6, and TNF production (Zhang et al., 2007).  
In addition, in a model of E.coli infection, human granulocytes and monocytes respond 
differentially to complement components or CD14, a component of the LPS receptor (Lappegard 
et al., 2009).  In contrast, C5a down-regulates IL-12 production in a TLR4 dependent manner 
(Hawlisch et al., 2005; Zhang et al., 2007).  Furthermore, complement regulates maturation and 
recruitment of cells expressing TLR4 (Fang et al., 2009; Spirig et al., 2008).  Treatment with 
dextran sulfate, a complement inhibitor, prevented TLR4-mediated dendritic cell maturation, 
while activation of both complement and TLR4 resulted in an infiltration of Th17 cells (Fang et 
al., 2009; Spirig et al., 2008).  Taken together, these data indicate that activation of either 
complement or TLR4 directly affects the activation of the other innate immune components.   
 
Since both TLR4 and complement play a role in IR-induced tissue damage, we examined the 
cross-regulation between the two innate immune components during intestinal IR.  Initial studies 
demonstrated that TLR4 deficiency inhibits IR-induced complement production and activation as 
well as intestinal damage.  Importantly, administration of the complement inhibitor, CR2-Crry, 
to wild-type or TLR4 deficient mice significantly reduced or eliminated complement activation 
products and C3 and FB mRNA.  However, CR2-Crry treatment reduced IR-induced intestinal 
damage only in wild-type mice, not TLR4 deficient mice.  Thus, a complex relationship exists 
between TLR4 and complement.
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MATERIALS AND METHODS 
Mice:  C57Bl/10 and B10/ScN mice were originally obtained from Jackson Laboratory and then 
bred and maintained in the Division of Biology at Kansas State University.  Housed in a 12-hour 
light-to-dark, temperature-controlled room, mice were allowed food and water ad libitum.  All 
mice were kept in specific pathogen free conditions (Helicobacter species, mouse hepatitis virus, 
minute virus of mice, mouse parvovirus, Sendai virus, murine norovirus, Mycoplasma pulmonis, 
Theiler’s murine encephalomyelitis virus, and endo- and ecto-parasites).  All research was 
approved by the Institutional Animal Care and Use Committee and conducted in compliance 
with the Animal Welfare Act and other Federal statutes and regulations concerning animals.   
 
Ischemia/Reperfusion:  Ischemia/reperfusion was performed on ketamine/xylazine anesthetized 
male 8-14 wk old mice (21-25 g) as described previously (Fleming et al., 2002).  Briefly, a 
midline laparotamy was performed and the mice were allowed to equilibrate for 30 minutes, with 
body temperature maintained at 37°C using a water-circulating heat pad.  Placing a warm, saline 
moistened piece of gauze over the abdominal cavity prevented peritoneal desiccation.  The 
superior mesenteric artery was identified, isolated, and a small vascular clamp applied for 30 
minutes and removed prior to 2 hours of reperfusion.  Ischemia was noted by the intestine 
changing from a pink color to a gray color.  Sham treated animals underwent the same procedure 
as the ischemic mice without occlusion of the superior mesenteric artery.  After two hours of 
reperfusion, the mice were euthanized and sera, liver, spleen, and 2 cm sections of the small 
intestine, approximately 10 cm distal to the gastroduodenal junction, were collected for 
histological and other analyses.  Mice treated with the targeted complement inhibitor, CR2-Crry, 
underwent the same procedures with i.v. administration of either 0.25mg CR2-Crry fusion 
 7 
protein or PBS control 10 min after clamp removal.  CR2-Crry was expressed and purified as 
described previously (Atkinson et al., 2005).   
 
Histology and Injury Scoring: A 2 cm mid-jejunum tissue section was immediately fixed in 
10% buffered formalin, embedded in paraffin, and 8μm sections were cut transversely and H+E 
stained.  Mucosal injury was graded on a six-tiered scale adapted from Chiu et al. (Chiu et al., 
1970) as described previously (Fleming et al., 2002).  Briefly, the average damage score of the 
intestinal section (75-150 villi) was determined after grading each villus from 0-6.  Normal villi 
were assigned a score of zero; villi with tip distortion were assigned a score of 1; a score of 2 
was assigned when Guggenheims’ spaces were present; villi with patchy disruption of the 
epithelial cells were assigned a score of 3; a score of 4 was assigned to villi with exposed but 
intact lamina propria with epithelial sloughing; a score of 5 was assigned when the lamina 
propria was exuding; last, villi that displayed hemorrhage or were denuded were assigned a score 
of 6. 
 
Ex vivo eicosanoid generation: Immediately after collection, a 2 cm intestinal section was 
minced, washed, resuspended in 37°C oxygenated Tyrode’s buffer (Sigma-Aldrich), incubated at 
37°C for 20 minutes and the supernatants collected.  PGE2 concentrations were determined using 
enzyme immunoassay kits (Cayman Chemical).  IL-6, IL-12p40, and IL-12p70 concentrations 
were determined using a Milliplex MAP immunoassay kit (Millipore) and read on a Luminex 
200 and analyzed with Milliplex Analyst software (Millipore).  All PGE2 and cytokine 
concentrations were standardized to the total tissue protein content determined by BCA assay 
(Pierce) adapted to microtiter plates. 
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Immunohistochemistry: After euthanasia, a 2 cm intestinal section was immediately snap 
frozen in O.C.T. freezing medium and 8 μm sections were placed on slides for 
immunohistochemistry.  The C3 and C3d deposition on the tissue sections was detected by 
staining with either a rat-anti-mouse C3 or C3d monoclonal antibody (Hycult Biotechnologies) 
followed by a texas-red conjugated secondary antibody (Jackson Immunoresearch).  Additional 
tissue sections were stained with appropriate isotype controls. Images were obtained using a 
Nikon eclipse 80i microscope equipped with a CoolSnap CF camera (Photometrics) and 
analyzed using Metavue software (Molecular Devices). C3 deposition was quantified using 
ImageJ software (NIH) by dividing the C3 antibody fluorescence area by the isotype control 
fluorescence area. 
 
C5a ELISA: Sera C5a concentrations were determined by capture ELISA (BD Biosciences).  
Briefly, NUNC-immulon plates (Thermo Fisher) were coated overnight at 4°C with rat-anti-
mouse C5a (BD Biosciences).  After blocking with 10% FBS for 1 hr at room temperature, ice 
cold sera was added in duplicate prior to addition of the Biotin detection antibody (BD 
Biosciences).  After addition of Avidin-HRP (BD Biosciences) and TMB (KPL), the ELISA was 
analyzed spectrophotometrically.  All samples were compared to a standard curve of purified 
mouse C5a.   
 
Real time PCR: Total RNA was isolated from the jejunum and liver using TRIzol reagent 
(Invitrogen) according to manufacturer’s instructions.  RNA integrity and genomic DNA 
contamination was assessed using a BioAnalyzer (Agilent) and quantity determined by 
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Nanodrop evaluation.  Only samples with no DNA contamination and RIN values greater than 
7.0 were used for cDNA synthesis.  Total RNA (2 ug) was reverse transcribed using RevertAid 
first strand cDNA synthesis kit (Fermentas) using random primers.  Quantitative real time PCR 
was performed in 25 ul volumes using a Mini-Opticon real time thermal cycler (Bio-Rad) and B-
R SYBR Green Supermix for iQ reagent (Quanta Biosciences) using the following protocol: 3m 
at 95°C; 50 cycles of 10s at 95°C, 20s at Tm (Table 1), 10s at 72°C; melt curve starting at 65°C, 
increasing 0.5°C every 5s up to 95°C. After amplification, TLR4, C3 and FB Ct values were 
normalized to 18s rRNA and then Ct fold change relative to Sham-treated wild-type mice was 
determined as described previously (Zhao et al., 2008).  Melt-curve analysis of the PCR products 
ensured amplification of a single product.   
 
Statistical Analysis:  Data are presented as mean ± 95% confidence interval (CI) and were 
compared by unpaired T test using the Mann-Whitney test (GraphPad Software).  
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RESULTS 
TLR4 is required for IR-induced complement activation 
Mesenteric IR induces intestinal damage and PGE2 production in wild-type mice which are 
attenuated but not totally absent in TLR4 deficient mice (Moses et al., 2009; Rehrig et al., 2001).  
IR-induced damage in wild-type mice is mediated by complement activation; however, the role 
of complement in the attenuated damage of TLR4 deficient mice is unclear. To determine if the 
limited damage and PGE2 production were complement mediated, we subjected wild-type 
(C57Bl/10) and TLR4 deficient (B10/ScN) mice to intestinal IR and compared C3 deposition on 
the intestinal tissue and serum C5a production.  Similar to previous studies, TLR4 deficiency 
attenuated IR-induced intestinal damage (Fig.1A).  After IR, intestinal tissues from wild-type 
mice (C57Bl/10) contained significant levels of C3 deposition when compared to Sham treated 
mice (Fig.1C-D). In contrast, mid-jejunal tissue sections from IR treated B10/ScN mice 
contained C3 deposits similar to the deposits observed in Sham treated mice and significantly 
fewer deposits compared to wild-type IR treated mice (Fig.1D).  In addition, compared to sham 
treatment, IR significantly elevated the serum C5a concentrations in wild-type mice but not 
TLR4 deficient mice (Fig.1B).   
 
Extrahepatic IR-induced Complement C3 and Factor B production requires TLR4 expression  
It was possible that IR increased production of complement proteins, either in the liver or locally 
in the intestine (Andoh et al., 1998; Laufer et al., 2000; Wang et al., 1998). Using real time PCR, 
we found that hepatic transcription of complement components C3 and FB did not change after 
IR in either wild-type or TLR4 deficient mice (Fig.2A and data not shown).  In contrast, IR 
induced a significant increase in the intestinal production of C3 (Fig.2B) and FB (Fig.2C) in 
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wild-type, but not TLR4 deficient mice. In addition, a significant increase in intestinal TLR4 
mRNA was observed in wild-type mice in response to IR (Fig. 2D). These results suggest that IR 
induces TLR4 expression which is required for increased extrahepatic production of C3 and FB.   
 
Attenuation of IR-induced intestinal inflammation in TLR4 deficient mice is further reduced by 
CR2-Crry treatment. 
Since mesenteric IR-induced damage and complement activation was attenuated, but not 
eliminated in TLR4 deficient mice, we hypothesized that complement inhibition would synergize  
with TLR4 deficiency. To test this hypothesis, we treated wild-type and TLR4 deficient mice 
with CR2-Crry. Treatment with CR2-Crry eliminated IR-induced C3 mRNA production by both 
strains of mice (Fig. 2B). In response to IR treatment, FB expression in wild-type but not TLR4 
deficient mice decreased with the inhibitor as well (Fig. 2C).  Surprisingly, CR2-Crry treatment 
significantly reduced TLR4 mRNA expression suggesting that complement also regulates TLR4 
expression. 
 
Examination of IR-induced mucosal injury indicated that in wild-type mice, administration of 
CR2-Crry during reperfusion attenuated mid-jejunal intestinal damage (Fig.3A-G).  Importantly, 
treatment with CR2-Crry did not further reduce IR-induced intestinal damage in B10/ScN mice 
(Fig. 3A, D, F, G).  Neither strain sustained intestinal damage after Sham treatment in the 
presence or absence of complement inhibitor.  Similar to previous studies, administration of 
CR2-Crry significantly decreased C3d deposition in all mice (Fig.4)  indicating that CR2-Crry 





Since TLR4 mediates PGE2 production during IR-induced intestinal damage, we examined the 
intestinal PGE2 concentrations after administration of CR2-Crry to wild-type and B10/ScN mice.  
Administration of CR2-Crry significantly reduced the IR-induced PGE2 production in wild-type 
mice despite the presence of TLR4 (Fig.5A).  However, CR2-Crry treatment did not alter PGE2 
production in the absence of TLR4 (Fig.5A).   
 
Complement activation inhibits TLR4 induced IL-12 secretion (Hawlisch et al., 2005; Zhang et 
al., 2007) and increases IL-6 production (Zhang et al., 2007).  Therefore, we hypothesized that 
complement inhibition would alter the expression profile of these cytokines.  We examined IL-6, 
IL-12p40 and IL-12p70 intestinal secretion in response to IR in both strains of mice, with and 
without CR2-Crry treatment.  As expected, IR resulted in elevated intestinal production of all 
three cytokines in wild-type mice (Fig.5B-D).  In contrast, levels of the pro-inflammatory 
cytokines, IL-6 and IL-12p70, remained the same in sham and IR treated TLR4 deficient 
B10/ScN mice (Fig.5B,C).  IL-12p40 increased moderately in TLR4 deficient mice subjected to 
IR (Fig.5D).  Inhibition of complement activation by CR2-Crry resulted in decreased production 
of IL-6 and both IL-12 family members in wild-type mice (Fig.5B-D).  In B10/ScN mice, CR2-
Crry significantly decreased the intestinal production of IL-6 and IL-12p40 (Fig.5B, D).  
Together these data suggest that TLR4 activation enhances complement mediated, IR-induced 
inflammation and damage.   
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DISCUSSION 
As innate immune components, both TLR4 and the complement cascade affect mesenteric IR-
induced tissue damage (Arumugam et al., 2009; Moses et al., 2009; Williams et al., 1999).  IR-
induced tissue damage is largely dependent on complement activation, an event that generates 
C3a and C5a chemotactic peptides (Fleming et al., 2003; Williams et al., 1999). In addition, 
activation of TLR4 results in the production of inflammatory chemokines, cytokines and 
eicosanoids during intestinal IR (Moses et al., 2009).  In other models of tissue damage, TLR4 
interacts with complement (Hawlisch and Kohl, 2006; Zhang et al., 2007).  The present study 
extends these findings and shows a complex bidirectional interaction between TLR4 and 
complement activation in intestinal IR-induced damage and inflammation. 
 
There are a limited number of studies examining the role of TLR4 activation during 
complement-mediated tissue damage with conflicting results.  A recent study indicated that 
alcohol-induced liver injury was complement-dependent, but TLR4 independent (Roychowdhury 
et al., 2009). In an LPS-induced mouse model of abortion, complement activation significantly 
enhanced TLR4- mediated tissue damage (Yu et al., 2008). In a recent study, the neutrophilic 
response to E.coli depended on complement components rather than CD14 (Lappegard et al., 
2009). In contrast, monocytic cytokine response varied depending on the cytokine (Lappegard et 
al., 2009).  Similarly, in response to intestinal IR, complement inhibition significantly decreased 
intestinal injury in wild-type mice. However, complement inhibition of TLR4 deficient mice 
resulted in no further decrease in injury and therefore was not synergistic.   Thus, damage is 
likely the sum of multiple inflammatory insults suggesting that each inflammatory component 
must be examined individually. This is illustrated by the fact that TLR4 deficiency inhibited 
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PGE2 and IL-6 production, but complement inhibition of the TLR4 deficient mice further 
reduced only IL-6 levels not PGE2 concentrations. In addition, in the absence of the complement 
inhibitor, DAF, complement enhanced IL-6 production in response to LPS (Zhang et al., 2007) 
suggesting that complement inhibitors regulate TLR4 cytokine production.  Together with the 
previous studies reported above, these data suggest that the relationship of TLR4 and 
complement activation differ based on the type of tissue damage and the mediator analyzed. 
 
Mesenteric IR induced significant complement activation in the intestine which was attenuated in 
the absence of TLR4, possibly due to the dependence of local C3 and FB transcription on TLR4.  
These results are similar to recent studies showing that TLR4 activation increases C3 and FB 
transcription in chondrocytes (Haglund et al., 2008), and that blocking TLR4 activation in Lewis 
lung carcinoma cells results in a 50% decrease of C3, C5 and C9 production (Stott and Korbelik, 
2007). Together, these data suggest a model (Fig. 6) in which IR activates both TLR4 and 
complement. In this model, complement activation enhances TLR4 stimulation and TLR4 
activation up-regulates complement protein synthesis (Fig. 6A), which in turn enhances local 
inflammation and injury. CR2-Crry inhibited complement activation and TLR4 transcription, as 
well as decreased cytokine, C3 and FB production (Fig. 6B). Similar to our findings with CR2-
Crry, DAF expression decreased TLR4 activation (Zhang et al., 2007) and dextran sulfate, an 
inhibitor of complement, decreased TLR4-mediated dendritic cell maturation (Spirig et al., 





The complexity of TLR4 and complement activation is further illustrated by the production of 
IL-12 family members. As a pro-inflammatory cytokine, IL-12p70 is composed of two subunits, 
IL-12p40 and IL-12p35.  The IL-12p40 subunit also complexes with either p19 to form IL-23, 
EBV-induced gene 3 to form IL-27, or another IL-12p40 subunit to form a homodimer (reviewed 
in (Cooper and Khader, 2007; Hunter, 2005)).  In wild-type mice, IR significantly increased 
intestinal concentrations of IL-12p70 and IL-12p40, while TLR4 deficiency attenuated, but did 
not eliminate, production of these cytokines after IR.  In addition, complement inhibition during 
reperfusion of the TLR4 deficient mice significantly reduced IL-12p40 concentrations to levels 
below that found in Sham treated mice. Similarly, C5 deficient macrophages produce 
significantly less IL-12p70 than TLR4 deficient macrophages after in vitro stimulation (Karp et 
al., 2000). In contrast, previous in vitro studies demonstrated that C5a treatment decreased LPS-
induced macrophage IL-12 production (Hawlisch and Kohl, 2006).   These data suggest that the 
mechanism of IR-induced IL-12 production may be different than that of LPS-induced IL-12 
production.  It is also possible that PGE2 regulates IR-induced IL-12 production, as both 
complement inhibition and TLR4 deficiency resulted in decreased PGE2 production.  Despite a 
slight increase in PGE2 concentrations after CR2-Crry treatment, there is no similar increase in 
IL-12p40 production. This may be due to normal variation within the intestine.  Previous in vitro 
studies indicated that PGE2 mediates IL-12p40 production by dendritic cells in the absence of  
IL-12p35  (Kalinski et al., 2001), while in vivo studies indicated that  PGE2 is TLR4 dependent 
(Moses et al., 2009).  Thus, complement may regulate IL-12p40 directly and indirectly by 
altering TLR4-regulated, PGE2 induction of IL-12p40.  
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In summary, we have demonstrated a complex relationship between TLR4 and the complement 
system during IR, and that this possible feedback loop is important in the subsequent 
inflammation and tissue injury. CR2-Crry, a targeted inhibitor that locally inhibits complement 
activation, further reduced IR-induced inflammation in the presence of TLR4. Thus, targeted 
therapeutics attenuate tissue damage without compromising the innate immune response.  
 17 
ACKNOWLEDGEMENTS 
The authors wish to thank Ms. Tiffany Moses and Mr. Andrew Fritze for excellent technical 
assistance. This work was supported by NIH Grants AI061691, P20 RR017686 and RR016475 
from the Institutional Development Award (IDeA) Program of the NCRR. 
 18 
REFERENCES 
Akira S. and Hemmi H., 2003. Recognition of pathogen-associated molecular patterns by TLR 
family. Immunol Lett 85, 85-95. 
Andoh A., Fujiyama Y., Sakumoto H., Uchihara H., Kimura T., Koyama S. and Bamba T., 1998. 
Detection of complement C3 and factor B gene expression in normal colorectal mucosa, 
adenomas and carcinomas. Clin. Exp. Immunol. 111, 477-83. 
Arumugam T. V., Okun E., Tang S. C., Thundyil J., Taylor S. M. and Woodruff T. M., 2009. 
Toll-like receptors in ischemia-reperfusion injury. Shock 32, 4-16. 
Atkinson C., Song H., Lu B., Qiao F., Burns T. A., Holers V. M., Tsokos G. C. and Tomlinson 
S., 2005. Targeted complement inhibition by C3d recognition ameliorates tissue injury 
without apparent increase in susceptibility to infection. J. Clin. Invest. 115, 2444-2453. 
Austen W. G., Kyriakides C., Favuzza J., Wang Y., Kobzik L., Moore F. D. and Hechtman H. 
B., 1999. Intestinal ischemia-reperfusion injury is mediated by the membrane attack 
complex. Surgery 126, 343-348. 
Chiu C.-J., McArdle A. H., Brown R., Scott H. J. and Gurd F. N., 1970. Intestinal mucosal lesion 
in low-flow states. Arch Surg. 101, 478-483. 
Clark J. A. and Coopersmith C. M., 2007. Intestinal crosstalk: a new paradigm for understanding 
the gut as the "motor" of critical illness. Shock 28, 384-93. 
Collard C. D., Lekowski R., Jordan J. E., Agah A. and Stahl G. L., 1999. Complement activation 
following oxidative stress. Mol. Immunol. 36, 941-948. 
Cooper A. M. and Khader S. A., 2007. IL-12p40: an inherently agonistic cytokine. Trends 
Immunol 28, 33-8. 
 19 
Deitch E. A., 2001. Role of the gut lymphatic system in multiple organ failure. Curr. Opin. Crit. 
Care 7, 92-8. 
El-Samalouti V. T., Schletter J., Chyla I., Lentschat A., Mamat U., Brade L., Flad H. D., Ulmer 
A. J. and Hamann L., 1999. Identification of the 80-kDa LPS-binding protein (LMP80) as 
decay-accelerating factor (DAF, CD55). FEMS Immunol. Med. Microbiol. 23, 259-69. 
Eror A. T., Stojadinovic A., Starnes B. W., Makrides S. C., Tsokos G. C. and Shea-Donohue T., 
1999. Anti-inflammatory effects of soluble complement receptor type 1 promote rapid 
recovery of ischemia/reperfusion injury in rat small intestine. Clin. Immunol. 90, 266-
275. 
Fang C., Zhang X., Miwa T. and Song W. C., 2009. Complement promotes the development of 
inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor 
signaling and interleukin-6 production. Blood 114, 1005-15. 
Fleming S. D., Mastellos D., Karpel-Massler G., Shea-Donohue T., Lambris J. D. and Tsokos G. 
C., 2003. C5a causes limited, polymorphonuclear cell-independent, mesenteric 
ischemia/reperfusion-induced injury. Clin. Immunol. 108, 263-273. 
Fleming S. D., Shea-Donohue T., Guthridge J. M., Kulik L., Waldschmidt T. J., Gipson M. G., 
Tsokos G. C. and Holers V. M., 2002. Mice deficient in complement receptors 1 and 2 
lack a tissue injury-inducing subset of the natural antibody repertoire. J. Immunol. 169, 
2126-2133. 
Fukata M., Chen A., Klepper A., Krishnareddy S., Vamadevan A. S., Thomas L. S., Xu R., Inoue 
H., Arditi M., Dannenberg A. J. and Abreu M. T., 2006. Cox-2 is regulated by Toll-like 
receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. 
Gastroenterology 131, 862-77. 
 20 
Fukata M., Chen A., Vamadevan A. S., Cohen J., Breglio K., Krishnareddy S., Hsu D., Xu R., 
Harpaz N., Dannenberg A. J., Subbaramaiah K., Cooper H. S., Itzkowitz S. H. and Abreu 
M. T., 2007. Toll-like receptor-4 promotes the development of colitis-associated 
colorectal tumors. Gastroenterology 133, 1869-81. 
Fukata M., Michelsen K. S., Eri R., Thomas L. S., Hu B., Lukasek K., Nast C. C., Lechago J., 
Xu R., Naiki Y., Soliman A., Arditi M. and Abreu M. T., 2005. Toll-like receptor-4 is 
required for intestinal response to epithelial injury and limiting bacterial translocation in a 
murine model of acute colitis. Am. J. Physiol. 288, G1055-1065. 
Haglund L., Bernier S. M., Önnerfjord P. and Recklies A. D., 2008. Proteomic analysis of the 
LPS-induced stress response in rat chondrocytes reveals induction of innate immune 
response components in articular cartilage. Matrix Biology 27, 107. 
Hawlisch H., Belkaid Y., Baelder R., Hildeman D., Gerard C. and Kohl J., 2005. C5a negatively 
regulates toll-like receptor 4-induced immune responses. Immunity 22, 415-26. 
Hawlisch H. and Kohl J., 2006. Complement and Toll-like receptors: key regulators of adaptive 
immune responses. Mol. Immunol. 43, 13-21. 
Heine H., Ulmer A. J., El-Samalouti V. T., Lentschat A. and Hamann L., 2001. Decay-
accelerating factor (DAF/CD55) is a functional active element of the LPS receptor 
complex. J Endotoxin Res 7, 227-31. 
Hunter C. A., 2005. New IL-12-family members: IL-23 and IL-27, cytokines with divergent 
functions. Nat. Rev. Immunol. 5, 521-31. 
Kalinski P., Vieira P. L., Schuitemaker J. H., de Jong E. C. and Kapsenberg M. L., 2001. 
Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and 
an inhibitor of bioactive IL-12p70 heterodimer. Blood 97, 3466-9. 
 21 
Karp C. L., Grupe A., Schadt E., Ewart S. L., Keane-Moore M., Cuomo P. J., Kohl J., Wahl L., 
Kuperman D., Germer S., Aud D., Peltz G. and Wills-Karp M., 2000. Identification of 
complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat 
Immunol 1, 221-6. 
Kilgore K. S., Todd R. F. and Lucchesi B. R., 1999. Reperfusion injury. In Gallin J. I. and 
Snyderman R. (Eds.), Lippincott Williams and Wilkins, Philadelphia, pp. 1047-1060. 
Lappegard K. T., Christiansen D., Pharo A., Thorgersen E. B., Hellerud B. C., Lindstad J., 
Nielsen E. W., Bergseth G., Fadnes D., Abrahamsen T. G., Hoiby E. A., Schejbel L., 
Garred P., Lambris J. D., Harboe M. and Mollnes T. E., 2009. Human genetic 
deficiencies reveal the roles of complement in the inflammatory network: lessons from 
nature. Proc Natl Acad Sci U S A 106, 15861-6. 
Laufer J., Oren R., Goldberg I., Horwitz A., Kopolovic J., Chowers Y. and Passwell J. H., 2000. 
Cellular localization of complement C3 and C4 transcripts in intestinal specimens from 
patients with Crohn's disease. Clin. Exp. Immunol. 120, 30-7. 
Leaphart C. L. and Tepas J. J., 3rd, 2007. The gut is a motor of organ system dysfunction. 
Surgery 141, 563-9. 
Makrides S. C., 1998. Therapeutic inhibition of the complement system. Pharmacol. Rev. 50, 59-
87. 
Makrides S. C., 2000. Complement inhibitors. In Tsokos G. C. (Ed.), Humana Press, Totowa, 
NJ. 
Mollen K. P., Anand R. J., Tsung A., Prince J. M., Levy R. M. and Billiar T. R., 2006. Emerging 
paradigm: toll-like receptor 4-sentinel for the detection of tissue damage. Shock 26, 430-
7. 
 22 
Moses T., Wagner L. M. and Fleming S. D., 2009. Tlr4 mediated cox-2 expression increases 
intestinal ischemia/reperfusion induced damage J. Leukoc. Biol. 86, 971-980. 
Quigg R. J., Kozono Y., Berthiaume D., Lim A., Salant D. J., Weinfeld A., Griffin P., Kremmer 
E. and Holers V. M., 1998. Blockade of antibody-induced glomerulonephritis with Crry-
Ig, a soluble murine complement inhibitor. J. Immunol. 160, 4553-4560. 
Rehrig S., Fleming S. D., Anderson J., Guthridge J. M., Rakstang J., McQueen C. E., Holers V. 
M., Tsokos G. C. and Shea-Donohue T., 2001. Complement inhibitor, complement 
receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of 
mesenteric ischemia/reperfusion injury in mice. J. Immunol. 167, 5921-7. 
Roychowdhury S., McMullen M. R., Pritchard M. T., Hise A. G., van Rooijen N., Medof M. E., 
Stavitsky A. B. and Nagy L. E., 2009. An early complement-dependent and TLR-4-
independent phase in the pathogenesis of ethanol-induced liver injury in mice. 
Hepatology 49, 1326-34. 
Spirig R., van Kooten C., Obregon C., Nicod L., Daha M. and Rieben R., 2008. The complement 
inhibitor low molecular weight dextran sulfate prevents TLR4-induced phenotypic and 
functional maturation of human dendritic cells. J. Immunol. 181, 878-90. 
Stott B. and Korbelik M., 2007. Activation of complement C3, C5, and C9 genes in tumors 
treated by photodynamic therapy. Cancer Immunol. Immunother. 56, 649-58. 
Triantafilou M., Brandenburg K., Gutsmann T., Seydel U. and Triantafilou K., 2002. Innate 
recognition of bacteria: engagement of multiple receptors. Crit. Rev. Immunol. 22, 251-
68. 
Tsan M.-F. and Gao B., 2004. Endogenous ligands of Toll-like receptors. J. Leukoc. Biol. 76, 
514-519. 
 23 
Wang Q., Meyer T. A., Boyce S. T., Wang J. J., Sun X., Tiao G., Fischer J. E. and Hasselgren P. 
O., 1998. Endotoxemia in mice stimulates production of complement C3 and serum 
amyloid A in mucosa of small intestine. Am. J. Physiol. 275, R1584-92. 
Williams J. P., Pechet T. T. V., Weiser M. R., Reid R., Kobzik L., Moore F. D., Carroll M. C. 
and Hechtman H. B., 1999. Intestinal reperfusion injury is mediated by IgM and 
complement. J. Appl. Physiol. 86, 938-942. 
Yu G., Sun Y., Foerster K., Manuel J., Molina H., Levy G. A., Gorczynski R. M. and Clark D. 
A., 2008. LPS-induced murine abortions require C5 but not C3, and are prevented by 
upregulating expression of the CD200 tolerance signaling molecule. Am. J. Reprod. 
Immunol. 60, 135-40. 
Zhang M. and Carroll M. C., 2006. Natural antibody mediated innate autoimmune response. 
Mol. Immunol. 
Zhang X., Kimura Y., Fang C., Zhou L., Sfyroera G., Lambris J. D., Wetsel R. A., Miwa T. and 
Song W. C., 2007. Regulation of Toll-like receptor-mediated inflammatory response by 
complement in vivo. Blood 110, 228-36. 
Zhao A., Urban J. F., Jr., Anthony R. M., Sun R., Stiltz J., Rooijen N. V., Wynn T. A., Gause W. 
C. and Shea-Donohue T., 2008. Th2 cytokine-induced alterations in intestinal smooth 




Figure 1.  TLR4 deficiency attenuates intestinal injury and complement activation.  A) 
Injury scores were determined from H+E stained intestinal sections scored as described in 
Materials and Methods. Each symbol is representative of an individual animal within the 
treatment group, with the line representing the average. B) Serum C5a activation was determined 
as stated in Materials and Methods. C-D) Frozen sections were stained for C3 deposition and 
quantified by Image J as described in Materials and Methods. Each bar represents a separate 
treatment group average ± 95% CI, with 6-12 samples per group. Photomicrographs for each 
treatment group (200X) are representative of 3 experiments of 5-7 photos per slide. The white 
bar represents 50m. Mann-Whitney analysis determined p-values; *p <0.05; ** p < 0.01; ***p 
< 0.001. 
 
Figure 2.  CR2-Crry significantly alters TLR4, C3 and Factor B transcription within the 
intestine.  Real time PCR ΔΔCt values were calculated for A) liver C3, B) intestinal C3, C) 
intestinal FB and D) intestinal TLR4 mRNA as described in Materials and Methods. Each bar 
represents a separate treatment group average ± CI, with 3-10 samples per group. Mann-




Figure 3.  CR2-Crry attenuates IR-induced intestinal injury in wild-type mice.   Injury 
scores (A) were determined from H+E stained intestinal sections scored as described in Materials 
and Methods.. Representative H&E stained intestinal sections are shown (B-G).  Each symbol 
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represents an individual animal within a separate treatment group, with the line representing the 
average. Mann-Whitney analysis determined p-values; *p <0.05; ** p < 0.01; ***p < 0.001. 
 
Figure. 4. CR2-Crry decreases C3d deposits within the intestine. Mid-jejunal sections from 
Sham or IR treated wild-type (C57Bl/10) and TLR4 deficient (B10/ScN) mice were stained for 
C3d deposition. Photomicrographs represent 3 experiments of 5-7 photos per treatment group. 
Each bar represents 50m.  
 
Figure 5.  Eicosanoid production in response to CR2-Crry.  A) PGE2, B) IL-6, C) IL-12p70, 
and D) IL-12p40 concentrations were determined as described in Materials and Methods.  Each 
bar represents a separate treatment group average ± 95% CI, with 4-8 samples per group. Mann-
Whitney analysis determined p-values; *p <0.05; ** p < 0.01; ***p < 0.001. 
 
Figure 6. Proposed interactions of TLR4 and complement in response to intestinal IR. IR 
induces complement activation which enhances TLR4 activation (A). IR also activates TLR4 
resulting in cytokine production and increased C3 and FB production (A). CR2-Crry inhibits 
both C3 and TLR4 activation (B).  
 
 
 Table I: Primer Sequences 
Gene Sense (5’ 3’) Antisense (5’ 3’) Tm (°C) Cycle # 
18s rRNA 5’GGTTGATCCTGCCAGTAGC 3’ 5’GCGACCAAAGGAACCATAAC 3’ 58 50 
C3 5’AAGCATCAACACACCCAACA 3’ 5’CTTGAGCTCCATTCGTGACA 3’ 58 50 
Factor B 5’CCAGCATTTGGGTTTCAGTT  3’ 5’CACACCTCCAGAGGAGAAGC 3’ 58 50 
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